Skip to main content
Erschienen in: Endocrine 3/2019

11.10.2018 | Original Article

Effects of dehydroepiandrosterone (DHEA) supplementation on sexual function in premenopausal infertile women

verfasst von: Vitaly A. Kushnir, Sarah K. Darmon, David H. Barad, Andrea Weghofer, Norbert Gleicher

Erschienen in: Endocrine | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To investigate the effects of dehydroepiandrosterone (DHEA) supplementation on female sexual function in premenopausal infertile women of advanced ages.

Methods

This observational study was conducted in an academically affiliated private fertility center. Patients included 87 premenopausal infertile women, 50 of whom completed the study including the Female Sexual Function Index (FSFI) questionnaires and comprehensive endocrine evaluation before and 4–8 weeks after initiating 25 mg of oral micronized DHEA TID.

Results

Age of patients was 41.1 ± 4.2 years, BMI 24.4 ± 6.1 kg/m2, 86% were married, and 42% were parous. Following supplementation with DHEA, all serum androgen levels increased (each P < 0.0001), while FSH levels decreased by 2.6 ± 4.4 from a baseline of 10.3 ± 5.4 mIU/mL (P = 0.009). The FSFI score for the whole study group increased by 7% (from 27.2 ± 6.9 to 29.2 ± 5.6; P = 0.0166). Domain scores for desire increased by 17% (P = 0.0004) and by 12% for arousal (P = 0.0122); lubrication demonstrated an 8% trend towards improvement (P = 0.0551), while no changes in domain scores for orgasm, satisfaction, or pain were observed. Women in the lowest starting FSFI score quartile (<25.7), experienced a 6.1 ± 8.0 (34%) increase in total FSFI score following DHEA supplementation. Among these women, improvements in domain categories were noted for desire (40%), arousal (46%), lubrication (33%), orgasm (54%), satisfaction (24%), and pain (25%).

Conclusions

This uncontrolled observational study implies that supplementation with DHEA improves sexual function in older premenopausal women with low baseline FSFI scores.
Literatur
1.
Zurück zum Zitat M.E. McCool, A. Zuelke, M.A. Theurich, H. Knuettel, C. Ricci, C. Apfelbacher, Prevalence of female sexual dysfunction among premenopausal women: a systematic review and meta-analysis of observational studies. Sex. Med. Rev. 4, 197–212 (2016)CrossRefPubMed M.E. McCool, A. Zuelke, M.A. Theurich, H. Knuettel, C. Ricci, C. Apfelbacher, Prevalence of female sexual dysfunction among premenopausal women: a systematic review and meta-analysis of observational studies. Sex. Med. Rev. 4, 197–212 (2016)CrossRefPubMed
3.
Zurück zum Zitat H.V. Joffe, C. Chang, C. Sewell, O. Easley, C. Nguyen, S. Dunn, K. Lehrfeld, L. Lee, M.J. Kim, A.F. Slagle, J. Beitz, FDA approval of flibanserin—treating hypoactive sexual desire disorder. N. Engl. J. Med. 374, 101–104 (2016)CrossRefPubMed H.V. Joffe, C. Chang, C. Sewell, O. Easley, C. Nguyen, S. Dunn, K. Lehrfeld, L. Lee, M.J. Kim, A.F. Slagle, J. Beitz, FDA approval of flibanserin—treating hypoactive sexual desire disorder. N. Engl. J. Med. 374, 101–104 (2016)CrossRefPubMed
4.
Zurück zum Zitat R. Basson, J. Berman, A. Burnett, L. Derogatis, D. Ferguson, J. Fourcroy, I. Goldstein, A. Graziottin, J. Heiman, E. Laan, S. Leiblum, H. Padma-Nathan, R. Rosen, K. Segraves, R.T. Segraves, R. Shabsigh, M. Sipski, G. Wagner, B. Whipple, Report of the international consensus development conference on female sexual dysfunction: definitions and classifications. J. Urol. 163, 888–893 (2000)CrossRefPubMed R. Basson, J. Berman, A. Burnett, L. Derogatis, D. Ferguson, J. Fourcroy, I. Goldstein, A. Graziottin, J. Heiman, E. Laan, S. Leiblum, H. Padma-Nathan, R. Rosen, K. Segraves, R.T. Segraves, R. Shabsigh, M. Sipski, G. Wagner, B. Whipple, Report of the international consensus development conference on female sexual dysfunction: definitions and classifications. J. Urol. 163, 888–893 (2000)CrossRefPubMed
5.
Zurück zum Zitat A.T. Guay, J. Jacobson, Decreased free testosterone and dehydroepiandrosterone-sulfate (DHEA-S) levels in women with decreased libido. J. Sex Marital Ther. 28(Suppl 1), 129–142 (2002)CrossRefPubMed A.T. Guay, J. Jacobson, Decreased free testosterone and dehydroepiandrosterone-sulfate (DHEA-S) levels in women with decreased libido. J. Sex Marital Ther. 28(Suppl 1), 129–142 (2002)CrossRefPubMed
6.
Zurück zum Zitat B. Turna, E. Apaydin, B. Semerci, B. Altay, N. Cikili, O. Nazli, Women with low libido: correlation of decreased androgen levels with female sexual function index. Int. J. Impot. Res. 17, 148–153 (2005)CrossRefPubMed B. Turna, E. Apaydin, B. Semerci, B. Altay, N. Cikili, O. Nazli, Women with low libido: correlation of decreased androgen levels with female sexual function index. Int. J. Impot. Res. 17, 148–153 (2005)CrossRefPubMed
7.
Zurück zum Zitat R.E. Nappi, To be or not to be in sexual desire: the androgen dilemma. Climacteric 18, 672–674 (2015)CrossRefPubMed R.E. Nappi, To be or not to be in sexual desire: the androgen dilemma. Climacteric 18, 672–674 (2015)CrossRefPubMed
8.
Zurück zum Zitat R. Worsley, R.J. Bell, P. Gartoulla, S.R. Davis, Prevalence and predictors of low sexual desire, sexually related personal distress, and hypoactive sexual desire dysfunction in a community-based sample of midlife women. J. Sex. Med. 14, 675–686 (2017)CrossRefPubMed R. Worsley, R.J. Bell, P. Gartoulla, S.R. Davis, Prevalence and predictors of low sexual desire, sexually related personal distress, and hypoactive sexual desire dysfunction in a community-based sample of midlife women. J. Sex. Med. 14, 675–686 (2017)CrossRefPubMed
9.
Zurück zum Zitat M.M. Kushnir, T. Blamires, A.L. Rockwood, W.L. Roberts, B. Yue, E. Erdogan, A.M. Bunker, A.W. Meikle, Liquid chromatography-tandem mass spectrometry assay for androstenedione, dehydroepiandrosterone, and testosterone with pediatric and adult reference intervals. Clin. Chem. 56, 1138–1147 (2010)CrossRefPubMed M.M. Kushnir, T. Blamires, A.L. Rockwood, W.L. Roberts, B. Yue, E. Erdogan, A.M. Bunker, A.W. Meikle, Liquid chromatography-tandem mass spectrometry assay for androstenedione, dehydroepiandrosterone, and testosterone with pediatric and adult reference intervals. Clin. Chem. 56, 1138–1147 (2010)CrossRefPubMed
10.
Zurück zum Zitat N. Orentreich, J.L. Brind, R.L. Rizer, J.H. Vogelman, Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J. Clin. Endocrinol. Metab. 59, 551–555 (1984)CrossRefPubMed N. Orentreich, J.L. Brind, R.L. Rizer, J.H. Vogelman, Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J. Clin. Endocrinol. Metab. 59, 551–555 (1984)CrossRefPubMed
11.
Zurück zum Zitat N. Gleicher, A. Kim, A. Weghofer, V.A. Kushnir, A. Shohat-Tal, E. Lazzaroni, H.J. Lee, D.H. Barad, Hypoandrogenism in association with diminished functional ovarian reserve. Hum. Reprod. 28, 1084–1091 (2013)CrossRefPubMed N. Gleicher, A. Kim, A. Weghofer, V.A. Kushnir, A. Shohat-Tal, E. Lazzaroni, H.J. Lee, D.H. Barad, Hypoandrogenism in association with diminished functional ovarian reserve. Hum. Reprod. 28, 1084–1091 (2013)CrossRefPubMed
12.
Zurück zum Zitat N. Gleicher, V.A. Kushnir, A. Weghofer, D.H. Barad, The importance of adrenal hypoandrogenism in infertile women with low functional ovarian reserve: a case study of associated adrenal insufficiency. Reprod. Biol. Endocrinol. 14, 23 (2016)CrossRefPubMedPubMedCentral N. Gleicher, V.A. Kushnir, A. Weghofer, D.H. Barad, The importance of adrenal hypoandrogenism in infertile women with low functional ovarian reserve: a case study of associated adrenal insufficiency. Reprod. Biol. Endocrinol. 14, 23 (2016)CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat P.J. Robinson, R.J. Bell, M.K. Christakis, S.R. Ivezic, S.R. Davis, Aromatase inhibitors are associated with low sexual desire causing distress and fecal incontinence in women: an observational study. J. Sex. Med. 14, 1566–1574 (2017)CrossRefPubMed P.J. Robinson, R.J. Bell, M.K. Christakis, S.R. Ivezic, S.R. Davis, Aromatase inhibitors are associated with low sexual desire causing distress and fecal incontinence in women: an observational study. J. Sex. Med. 14, 1566–1574 (2017)CrossRefPubMed
14.
Zurück zum Zitat S.R. Davis, R. Worsley, K.K. Miller, S.J. Parish, N. Santoro, Androgens and female sexual function and dysfunction—findings from the Fourth International Consultation of Sexual Medicine. J. Sex. Med. 13, 168–178 (2016)CrossRefPubMed S.R. Davis, R. Worsley, K.K. Miller, S.J. Parish, N. Santoro, Androgens and female sexual function and dysfunction—findings from the Fourth International Consultation of Sexual Medicine. J. Sex. Med. 13, 168–178 (2016)CrossRefPubMed
15.
Zurück zum Zitat M. Khera, Testosterone therapy for female sexual dysfunction. Sex. Med. Rev. 3, 137–144 (2015)CrossRefPubMed M. Khera, Testosterone therapy for female sexual dysfunction. Sex. Med. Rev. 3, 137–144 (2015)CrossRefPubMed
16.
Zurück zum Zitat M. Panjari, S.R. Davis, DHEA therapy for women: effect on sexual function and wellbeing. Hum. Reprod. Update 13, 239–248 (2007)CrossRefPubMed M. Panjari, S.R. Davis, DHEA therapy for women: effect on sexual function and wellbeing. Hum. Reprod. Update 13, 239–248 (2007)CrossRefPubMed
17.
Zurück zum Zitat R.F. Spark, Dehydroepiandrosterone: a springboard hormone for female sexuality. Fertil. Steril. 77(Suppl 4), S19–S25 (2002)CrossRefPubMed R.F. Spark, Dehydroepiandrosterone: a springboard hormone for female sexuality. Fertil. Steril. 77(Suppl 4), S19–S25 (2002)CrossRefPubMed
18.
Zurück zum Zitat C.S. Scheffers, S. Armstrong, A.E. Cantineau, C. Farquhar, V. Jordan, Dehydroepiandrosterone for women in the peri- or postmenopausal phase. Cochrane Database Syst. Rev. 1, CD011066 (2015)PubMed C.S. Scheffers, S. Armstrong, A.E. Cantineau, C. Farquhar, V. Jordan, Dehydroepiandrosterone for women in the peri- or postmenopausal phase. Cochrane Database Syst. Rev. 1, CD011066 (2015)PubMed
19.
Zurück zum Zitat W. Arlt, F. Callies, J.C. van Vlijmen, I. Koehler, M. Reincke, M. Bidlingmaier, D. Huebler, M. Oettel, M. Ernst, H.M. Schulte, B. Allolio, Dehydroepiandrosterone replacement in women with adrenal insufficiency. N. Engl. J. Med. 341, 1013–1020 (1999)CrossRefPubMed W. Arlt, F. Callies, J.C. van Vlijmen, I. Koehler, M. Reincke, M. Bidlingmaier, D. Huebler, M. Oettel, M. Ernst, H.M. Schulte, B. Allolio, Dehydroepiandrosterone replacement in women with adrenal insufficiency. N. Engl. J. Med. 341, 1013–1020 (1999)CrossRefPubMed
20.
Zurück zum Zitat F. Labrie, D.F. Archer, W. Koltun, A. Vachon, D. Young, L. Frenette, D. Portman, M. Montesino, I. Côté, J. Parent, L. Lavoie, A. Beauregard, C. Martel, M. Vaillancourt, J. Balser, É. Moyneur; VVA Prasterone Research Group, Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause 23, 243–256 (2016)CrossRefPubMed F. Labrie, D.F. Archer, W. Koltun, A. Vachon, D. Young, L. Frenette, D. Portman, M. Montesino, I. Côté, J. Parent, L. Lavoie, A. Beauregard, C. Martel, M. Vaillancourt, J. Balser, É. Moyneur; VVA Prasterone Research Group, Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause 23, 243–256 (2016)CrossRefPubMed
21.
Zurück zum Zitat N. Gleicher, D.H. Barad, Dehydroepiandrosterone (DHEA) supplementation in diminished ovarian reserve (DOR). Reprod. Biol. Endocrinol. 9, 67 (2011)CrossRefPubMedPubMedCentral N. Gleicher, D.H. Barad, Dehydroepiandrosterone (DHEA) supplementation in diminished ovarian reserve (DOR). Reprod. Biol. Endocrinol. 9, 67 (2011)CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat N. Gleicher, A. Kim, A. Weghofer, A. Shohat-Tal, E. Lazzaroni, H.J. Lee, D.H. Barad, Starting and resulting testosterone levels after androgen supplementation determine at all ages in vitro fertilization (IVF) pregnancy rates in women with diminished ovarian reserve (DOR). J. Assist. Reprod. Genet. 30, 49–62 (2013)CrossRefPubMed N. Gleicher, A. Kim, A. Weghofer, A. Shohat-Tal, E. Lazzaroni, H.J. Lee, D.H. Barad, Starting and resulting testosterone levels after androgen supplementation determine at all ages in vitro fertilization (IVF) pregnancy rates in women with diminished ovarian reserve (DOR). J. Assist. Reprod. Genet. 30, 49–62 (2013)CrossRefPubMed
23.
Zurück zum Zitat N. Gleicher, A. Weghofer, D.H. Barad, Improvement in diminished ovarian reserve after dehydroepiandrosterone supplementation. Reprod. Biomed. Online 21, 360–365 (2010)CrossRefPubMed N. Gleicher, A. Weghofer, D.H. Barad, Improvement in diminished ovarian reserve after dehydroepiandrosterone supplementation. Reprod. Biomed. Online 21, 360–365 (2010)CrossRefPubMed
24.
Zurück zum Zitat D. Barad, H. Brill, N. Gleicher, Update on the use of dehydroepiandrosterone supplementation among women with diminished ovarian function. J. Assist. Reprod. Genet. 24, 629–634 (2007)CrossRefPubMedPubMedCentral D. Barad, H. Brill, N. Gleicher, Update on the use of dehydroepiandrosterone supplementation among women with diminished ovarian function. J. Assist. Reprod. Genet. 24, 629–634 (2007)CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat A. Sen, S.R. Hammes, Granulosa cell-specific androgen receptors are critical regulators of ovarian development and function. Mol. Endocrinol. 24, 1393–1403 (2010)CrossRefPubMedPubMedCentral A. Sen, S.R. Hammes, Granulosa cell-specific androgen receptors are critical regulators of ovarian development and function. Mol. Endocrinol. 24, 1393–1403 (2010)CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat A. Sen, H. Prizant, A. Light, A. Biswas, E. Hayes, H.J. Lee, D. Barad, N. Gleicher, S.R. Hammes, Androgens regulate ovarian follicular development by increasing follicle stimulating hormone receptor and microRNA-125b expression. Proc. Natl. Acad. Sci. U.S.A. 111, 3008–3013 (2014)CrossRefPubMedPubMedCentral A. Sen, H. Prizant, A. Light, A. Biswas, E. Hayes, H.J. Lee, D. Barad, N. Gleicher, S.R. Hammes, Androgens regulate ovarian follicular development by increasing follicle stimulating hormone receptor and microRNA-125b expression. Proc. Natl. Acad. Sci. U.S.A. 111, 3008–3013 (2014)CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat L.T. Lin, P.H. Wang, S.N. Chen, C.J. Li, Z.H. Wen, J.T. Cheng, K.H. Tsui, Protection of cumulus cells following dehydroepiandrosterone supplementation. Gynecol. Endocrinol. 33, 100–104 (2017)CrossRefPubMed L.T. Lin, P.H. Wang, S.N. Chen, C.J. Li, Z.H. Wen, J.T. Cheng, K.H. Tsui, Protection of cumulus cells following dehydroepiandrosterone supplementation. Gynecol. Endocrinol. 33, 100–104 (2017)CrossRefPubMed
28.
Zurück zum Zitat H. Prizant, N. Gleicher, A. Sen, Androgen actions in the ovary: balance is key. J. Endocrinol. 222, R141–R151 (2014)CrossRefPubMed H. Prizant, N. Gleicher, A. Sen, Androgen actions in the ovary: balance is key. J. Endocrinol. 222, R141–R151 (2014)CrossRefPubMed
29.
Zurück zum Zitat C.R. Mendonça, J.T. Arruda, M. Noll, P.M.O. Campoli, W.N.D. Amaral, Sexual dysfunction in infertile women: a systematic review and meta-analysis. Eur. J. Obstet. Gynecol. Reprod. Biol. 215, 153–163 (2017)CrossRefPubMed C.R. Mendonça, J.T. Arruda, M. Noll, P.M.O. Campoli, W.N.D. Amaral, Sexual dysfunction in infertile women: a systematic review and meta-analysis. Eur. J. Obstet. Gynecol. Reprod. Biol. 215, 153–163 (2017)CrossRefPubMed
30.
Zurück zum Zitat L.S. Millheiser, A.E. Helmer, R.B. Quintero, L.M. Westphal, A.A. Milki, R.B. Lathi, Is infertility a risk factor for female sexual dysfunction? A case-control study. Fertil. Steril. 94, 2022–2025 (2010)CrossRefPubMed L.S. Millheiser, A.E. Helmer, R.B. Quintero, L.M. Westphal, A.A. Milki, R.B. Lathi, Is infertility a risk factor for female sexual dysfunction? A case-control study. Fertil. Steril. 94, 2022–2025 (2010)CrossRefPubMed
31.
Zurück zum Zitat R. Rosen, C. Brown, J. Heiman, S. Leiblum, C. Meston, R. Shabsigh, D. Ferguson, R. D’Agostino, The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J. Sex Marital Ther. 26, 191–208 (2000)CrossRefPubMed R. Rosen, C. Brown, J. Heiman, S. Leiblum, C. Meston, R. Shabsigh, D. Ferguson, R. D’Agostino, The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J. Sex Marital Ther. 26, 191–208 (2000)CrossRefPubMed
32.
Zurück zum Zitat A. Shohat-Tal, A. Sen, D.H. Barad, V. Kushnir, N. Gleicher, Genetics of androgen metabolism in women with infertility and hypoandrogenism. Nat. Rev. Endocrinol. 11, 429–441 (2015)CrossRefPubMed A. Shohat-Tal, A. Sen, D.H. Barad, V. Kushnir, N. Gleicher, Genetics of androgen metabolism in women with infertility and hypoandrogenism. Nat. Rev. Endocrinol. 11, 429–441 (2015)CrossRefPubMed
33.
Zurück zum Zitat N. Gleicher, K. Seier, V.A. Kushnir, A. Weghofer, Y.G. Wu, Q. Wang, D.F. Albertini, D.H. Barad, Associations between peripheral androgens and cortisol in infertile women. J Steroid Biochem Mol Biol. 2016 Apr;158, 82-89 N. Gleicher, K. Seier, V.A. Kushnir, A. Weghofer, Y.G. Wu, Q. Wang, D.F. Albertini, D.H. Barad, Associations between peripheral androgens and cortisol in infertile women. J Steroid Biochem Mol Biol. 2016 Apr;158, 82-89
34.
Zurück zum Zitat M. Stomati, P. Monteleone, E. Casarosa, B. Quirici, S. Puccetti, F. Bernardi, A.D. Genazzani, L. Rovati, M. Luisi, A.R. Genazzani, Six-month oral dehydroepiandrosterone supplementation in early and late postmenopause. Gynecol. Endocrinol. 14, 342–363 (2000)CrossRefPubMed M. Stomati, P. Monteleone, E. Casarosa, B. Quirici, S. Puccetti, F. Bernardi, A.D. Genazzani, L. Rovati, M. Luisi, A.R. Genazzani, Six-month oral dehydroepiandrosterone supplementation in early and late postmenopause. Gynecol. Endocrinol. 14, 342–363 (2000)CrossRefPubMed
35.
Zurück zum Zitat J.M. Weinberger, J. Houman, A.T. Caron, D.N. Patel, A.S. Baskin, A.L. Ackerman, K.S. Eilber, J.T. Anger, Female sexual dysfunction and the placebo effect: a meta-analysis. Obstet. Gynecol. 132(2), 453–458 (2018)CrossRefPubMed J.M. Weinberger, J. Houman, A.T. Caron, D.N. Patel, A.S. Baskin, A.L. Ackerman, K.S. Eilber, J.T. Anger, Female sexual dysfunction and the placebo effect: a meta-analysis. Obstet. Gynecol. 132(2), 453–458 (2018)CrossRefPubMed
36.
Zurück zum Zitat J.L. Shifren, B.U. Monz, P.A. Russo, A. Segreti, C.B. Johannes, Sexual problems and distress in United States women: prevalence and correlates. Obstet. Gynecol. 112, 970–978 (2008)CrossRefPubMed J.L. Shifren, B.U. Monz, P.A. Russo, A. Segreti, C.B. Johannes, Sexual problems and distress in United States women: prevalence and correlates. Obstet. Gynecol. 112, 970–978 (2008)CrossRefPubMed
Metadaten
Titel
Effects of dehydroepiandrosterone (DHEA) supplementation on sexual function in premenopausal infertile women
verfasst von
Vitaly A. Kushnir
Sarah K. Darmon
David H. Barad
Andrea Weghofer
Norbert Gleicher
Publikationsdatum
11.10.2018
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 3/2019
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-018-1781-3

Weitere Artikel der Ausgabe 3/2019

Endocrine 3/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.